Back to top
more

Emergent Biosolutions (EBS)

(Delayed Data from NYSE)

$5.95 USD

5.95
745,576

+0.32 (5.68%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $5.96 +0.01 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for August 7th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 7th

Zacks Equity Research

ACADIA (ACAD) Q2 Earnings Surpass, Nuplazid Drives Sales

by Zacks Equity Research

ACADIA (ACAD) beats on earnings and revenues for the second quarter. The company lifts the lower end of its net sales view for Nuplazid, driving the stock in pre-market trading.

Zacks Equity Research

Emergent Biosolutions (EBS) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Emergent Biosolutions (EBS) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

Horizon (HZNP) Q2 Earnings Down Y/Y, Tepezza Drives Sales

by Zacks Equity Research

Horizon Therapeutics' (HZNP) earnings decline year over year and sales beat estimates in the second quarter of 2020.

Zacks Equity Research

Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis (ZTS) beats both earnings and sales estimates in the second quarter of 2020.

Zacks Equity Research

Allogene's (ALLO) Q2 Loss Widens Y/Y, Pipeline Progresses

by Zacks Equity Research

Allogene (ALLO) reports no revenues for the second quarter of 2020.

Zacks Equity Research

Sarepta (SRPT) Q2 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Sarepta (SRPT) Q2 revenues increase year over year.

Zacks Equity Research

Emergent BioSolutions' Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Emergent BioSolutions.

Zacks Equity Research

Arena Pharmaceuticals (ARNA) Q2 Loss Narrower Than Expected

by Zacks Equity Research

Arena Pharmaceuticals (ARNA) beats bottom-line estimates for the second quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.

Zacks Equity Research

BioDelivery (BDSI) Q2 Earnings Miss, Revenues Beat, Stock Up

by Zacks Equity Research

BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues. Stock up.

Nitish Marwah headshot

4 Solid Momentum Picks Screened on Driehaus Strategy

by Nitish Marwah

Investors who have the tendency to take a high level of risk can choose momentum stocks.

Zacks Equity Research

Perrigo (PRGO) Q2 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Perrigo (PRGO) reports decent second-quarter 2020 results. The addition of products following Ranir acquisition boosts sales in the quarter.

Zacks Equity Research

Jazz Pharma (JAZZ) Beats on Q2 Earnings & Sales, Raises View

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) reports better-than-expected second-quarter 2020 earnings and revenues. It raises its guidance for 2020. Shares rise.

Zacks Equity Research

BioMarin (BMRN) Q2 Earnings Top, Sales Show Coronavirus Impact

by Zacks Equity Research

BioMarin (BMRN) reports better-than-expected second-quarter results. The company maintains its previously issued guidance for 2020.

Zacks Equity Research

Amarin (AMRN) Beats on Q2 Earnings, Focuses on Europe

by Zacks Equity Research

Amarin's (AMRN) revenue growth in the second quarter is attributable to continued demand for its cardiovascular drug, Vascepa.

Zacks Equity Research

Coronavirus Vaccine Efforts Key to Vaxart (VXRT) Q2 Earnings

by Zacks Equity Research

Vaxart (VXRT) has been working on developing a coronavirus vaccine. Increased clinical activity is expected to have increased expenses.

Zacks Equity Research

Emergent (EBS) Beats Q2 Earnings Estimates, Ups '20 Guidance

by Zacks Equity Research

Emergent's (EBS) second-quarter earnings beat estimates on robust product sales. Concurrently, it increases its annual guidance.

Zacks Equity Research

Ultragenyx (RARE) Loss Narrows Y/Y & Revenues Beat Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports a narrower-than-expected loss in the second quarter of 2020 and beats sales estimates.

Zacks Equity Research

Blueprint Medicines' (BPMC) Q2 Earnings Miss, Revenues Beat

by Zacks Equity Research

Blueprint Medicines (BPMC) posts a wider-than-expected loss but revenues beat estimates in the second quarter of 2020.

Zacks Equity Research

Seattle Genetics (SGEN) Q2 Earnings Beat, Adcetris Aids Sales

by Zacks Equity Research

Seattle Genetics (SGEN) reports a narrower-than-expected loss and beats sales estimates in the second quarter of 2020.

Zacks Equity Research

Alexion (ALXN) Beats on Q2 Earnings & Sales, Ups '20 Guidance

by Zacks Equity Research

Alexion (ALXN) beats on earnings and sales in the second quarter of 2020.

Zacks Equity Research

Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase

by Zacks Equity Research

Dr. Reddy's (RDY) earnings and revenues decline year over year in first-quarter fiscal 2021.

Zacks Equity Research

Alkermes' (ALKS) Q2 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Alkermes' (ALKS) earnings decline year over year in the second quarter of 2020.

Zacks Equity Research

Biotech Stock Roundup: Amgen Reports Q2, GILD's CAR T Therapy Gets Approval & More

by Zacks Equity Research

The biotech sector remains in focus with earnings, regulatory and other pipeline updates.

Zacks Equity Research

Is Emergent Biosolutions (EBS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (EBS) Outperforming Other Medical Stocks This Year?